Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 181Recurrence 32Neoplasms, Plasma Cell 16Lymphoma 11Waldenstrom Macroglobulinemia 6Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Smoldering Multiple Myeloma 4Leukemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Plasma Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1

Interventions

fludarabine phosphate 41Cyclophosphamide 31Mycophenolic Acid 25Whole-Body Irradiation 23Peripheral Blood Stem Cell Transplantation 21Cyclosporine 17Rituximab 16Tacrolimus 15fludarabine 14Antilymphocyte Serum 14Busulfan 12Filgrastim 10Cyclosporins 10Methotrexate 8Sirolimus 7Therapeutics 6Melphalan 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Psychiatric Rehabilitation 4Pharmacogenomic Testing 4Lenalidomide 4Carboplatin 4Allopurinol 4alvocidib 3Thiotepa 3Flow Cytometry 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × carfilzomib × Clear all
NCT01212380 2016-05-09

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡